Dr. Meng has more than 15-year research experience in molecular biology, small molecule drug and pharmacology, as well as over 10-year experience of drug development and management in pharma industry. He is familiar with the overall process of drug R&D ranging from research to clinic, from market to venture. He also stays in touch with the latest progress in biopharma domestic and abroad. He maintains a broad network with researchers, industrialists, entrepreneurs and investors. Dr. Meng was CEO of a traditional Chinese medicine technology company and Chief Technical Officer of Jianxin Pharmaceuticals Co., Ltd. Dr. Meng received Ph.D. degree of Biochemistry from Chinese Academy of Sciences. He completed postdoctoral training in Harvard and Washington University School of Medicine, and he also received MPA degree from Kennedy School at Harvard. Dr. Meng was Beijing Scientific Leader Program.
Baoping Wang, Ph.D. Chief Operation Officer
Dr. Wang has 15-year research experience in molecular biology and immunology followed by 20 years’ experience in novel drug research and development and management of R&D operations. He received a BS degree in Applied Chemistry from Shanghai Jiao Tong University and a PhD in Genetics from University of Minnesota. He completed his postdoc research at Harvard Medical School where he then served as an Instructor and Assistant Professor. He returned China in 1998 to join industry. From Jan 2001 to July 2018, he served sequentially as the head of Novo Nordisk R&D center China, Vice President of Novo Nordisk R&D, and the President of Novo Nordisk Research Center China, responsible for the R&D center’s overall operations and site management, and played a pivotal role in developing the center to be one of the largest R&D centers by multinational pharmaceutical companies in China, and an important site of Novo Nordisk R&D organization.
Charlie Wang, Ph.D. Chief Science Officer.
Dr. Wang is a Member of Board of Directors. He received Ph.D. degree from Washington University at St. Louis. He completed postdoctoral training in Princeton University, and was Assistant Professor of Harvard Medical School. Dr. Wang was a professor of pathology in Creighton University, director of an oncology laboratory when he founded Shenogen together with Dr. Kun Meng. Dr. Wang has over 20-year experience in cancer research. He is expert in molecular cancer biology, especially cell proliferation, differentiation and apoptosis. Dr. Wang is dedicated to study breast cancer related genes. He identified and cloned a novel membrane estrogen receptor ER-alpha 36 and studied its functions. His findings greatly contributed to the understanding of the pathogenesis of breast cancer, and got high remarks from Elwood Jensen, fellow of National Academy of Sciences and V. Craig Jordan, “Father of Tamoxifen”. Dr. Wang received grants from NIH, American Cancer Society, the US Department of Defense and Susan G. Komen Foundation. Dr. Wang has authored/ co-authored more than 70 peer-reviewed papers, host and attended many key scientific conferences, written four books and owned three granted patents. Dr. Wang returned China in 2014. He was Shandong Taishan Academician Program.
Jian Peng, Ph.D. Senior Vice President
Dr. Peng is responsible for regulatory affairs and drug development strategy. Dr. Peng has high reputation in drug regulatory and drug development, and has worked in the field for the last 20 years. Prior to joining Shenogen, he served as scientific advisor, director of clinical research & oncology head of Asia Pacific, Sanofi, sequentially. Before that, Dr. Peng was in charge of oncology drug approval in Center of Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA). He was lead director of the program for oncology drug clinical research and evaluation, which helped to improve quality of clinical trials in China. Dr. Peng played a key role in leading several Chinese first-in-class oncology drugs to approval, including Icotinib from BettaPharma, Apatinib from Heng Rui Medicine, Chidamide from Chipscreen. He was also the leader of Oxaliplatin (Sanofi) clinical trials and regulatory process in China. Dr. Peng got his PhD degree from China Pharmaceutical University and master degree from China Academy of Chinese Medicine Sciences. Dr. Peng is author/co-author of more than 20 SCI papers and serves as a member of Chinese Society of Clinical Oncology (CSCO).
Hong Guo, M.D.Chief Medical Officer and Vice President for Clinical Development
Dr. Guo has more than 20 years of experience in clinical development, and has led many clinical research programs at several multinational pharmaceutical companies, including Novartis, GSK, Novo Nordisk, Pfizer and MSD. He is very strong in the execution of clinical development and has insights in clinical trial practices. Dr. Guo is well connected with oncology clinical trial PIs in many large hospitals in China, and led many successful Phase III oncology trial programs. He received his MD degree from the Capital Medical University and started his career as an anesthetist at the Beijing Chest Tumor Hospital, and later on received an MBA degree from the University of East London. He also acts as the chairman for the RDPAC Clinical Operations before joining in Shenogen, has strong management and practice experience in clinical research area.
John FeiSenior Vice President
Mr. Fei received his MBA degree from the Business School of Columbia University. Mr. Fei has over 20 years of experience in investment banking and securities. He served as CEO at Kim Eng Securities (Hong Kong), and also served as senior position in many international financial institutions such as Merrill Lynch Group, Deutsche Bank and ICBC International.